Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin vs dapagliflozin in metabolic syndrome
IRCT20250712066463N1Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of metformin and dapagliflozin in cardiometabolic risk (CMR) (2 arms), sponsored by Babol University of Medical Sciences. Started Jul 2025; status: completed.
02
Drugs
metformindapagliflozin
03
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on IRCT20250712066463N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250712066463N1.